In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.
All people affected by TB have a right to benefit from scientific progress and to access the best-available short-course regimens for TB prevention and treatment. The 1/4/6x24 Campaign demands that countries and other duty bearers take action to implement the…
On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than they’ve been since the early 2000s, setting back an already woefully inadequate effort to end the disease.
Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.
Inspired by the legacy of Dr. Paul Farmer, the 1 / 4 / 6 x 24 Campaign calls for the “staff, stuff, space, systems and support” necessary to make groundbreaking short-course TB prevention and treatment regimens accessible to all who need them as a human right by the end of 2024.
TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not…
Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…
Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.